Suomi -
suomi -
Fimea (Suomen lääkevirasto)
cefepim mip pharma 2 g injektio/infuusiokuiva-aine, liuosta varten
mip pharma gmbh - cefepime - injektio/infuusiokuiva-aine, liuosta varten - 2 g - kefepiimi
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
viant infuusiokuiva-aine, liuosta varten
b. braun melsungen ag - ascorbic acid, biotin, colecalciferol, cyanocobalamin, riboflavin sodium fosfate, nicotinamide, pyridoxine hydrochloride, retinol palmitate, thiamine hydrochloride, all-rac-alfa-tocopherol, pantothenic acid, all-rac-phytomenadione, folic acid hydrate - infuusiokuiva-aine, liuosta varten - 932 mg - vitamiinit
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
osteopen vet 100 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - pentosan polysulfate sodium - injektioneste, liuos - 100 mg/ml - pentosaanipolysulfaatti
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
sibnayal
advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulaarinen estäminen - kaikki muut terapeuttiset tuotteet - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
lacosamide adroiq
extrovis eu ltd. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.